These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38247866)

  • 1. Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species.
    Ogawa Y; Ueda TP; Obara K; Nishimura K; Kamura T
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
    Xie H; Zhang C
    Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro autoubiquitination activity of E3 ubiquitin ligases of the N-degron pathway.
    Sandmann A; Dissmeyer N
    Methods Enzymol; 2023; 686():205-220. PubMed ID: 37532400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Lys-ϵ-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1.
    Thompson JW; Nagel J; Hoving S; Gerrits B; Bauer A; Thomas JR; Kirschner MW; Schirle M; Luchansky SJ
    J Biol Chem; 2014 Oct; 289(42):28942-55. PubMed ID: 25147182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin proteasome system in immune regulation and therapeutics.
    Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
    Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
    Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
    Burande CF; Heuzé ML; Lamsoul I; Monsarrat B; Uttenweiler-Joseph S; Lutz PG
    Mol Cell Proteomics; 2009 Jul; 8(7):1719-27. PubMed ID: 19376791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Eukaryotic Proteome Is Shaped by E3 Ubiquitin Ligases Targeting C-Terminal Degrons.
    Koren I; Timms RT; Kula T; Xu Q; Li MZ; Elledge SJ
    Cell; 2018 Jun; 173(7):1622-1635.e14. PubMed ID: 29779948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
    Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
    Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
    Belcher BP; Ward CC; Nomura DK
    Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of misfolded protein in the cytoplasm is mediated by the ubiquitin ligase Ubr1.
    Eisele F; Wolf DH
    FEBS Lett; 2008 Dec; 582(30):4143-6. PubMed ID: 19041308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Proteasome-Associated Ubiquitin Ligase Activity.
    Wang Z; Orosa-Puente B; Spoel SH
    Methods Mol Biol; 2023; 2581():57-67. PubMed ID: 36413310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.